Apolipoprotein E ε4 allele is a risk factor for familial and sporadic presenile Alzheimer’s disease in both homozygote and heterozygote carriers

David St Clair, Morag Rennie, Euan Slorach, Jennie Normman, Celia Yates, Andrew Carothers

Abstract
While apolipoprotein E (ApoE) ε4 allele is now a well established risk factor for familial and sporadic senile Alzheimer's disease (AD), its role in the development of the rarer presenile or early onset type is controversial. Early studies showed no association; later on, ε4 was enriched for the ε4 allele in familial or sporadic types or both. We have ApoE genotyped a series of Scottish people (n = 85) with early onset AD. We find highly significant enrichment for both homozygote and heterozygote ApoE ε4 allele carriers in familial and sporadic early onset AD with a pattern closely resembling that in late onset AD.

(J Med Genet 1995;32:642-644)

AD is a neurodegenerative disorder characterised by β amyloid peptide deposits in senile plaques and cerebral blood vessel walls, and neurofibrillary tangles (NFTs) within neurones of the cerebral cortex and hippocampus. ApoE has been found localised to senile plaques, vascular amyloid, and NFTs and one allele, ε4, is significantly associated with familial and sporadic late onset AD. ApoE is a 34 kDa protein that is involved in cholesterol and triglyceride transport, mediating their clearance from plasma by interaction with low density lipoprotein receptor. Unlike other lipoproteins which are mainly synthesised in the liver, ApoE is also synthesised in astrocytes and oligodendrocytes in the central nervous system. It has three isoforms corresponding to alleles ε2, ε3, and ε4. The isoform corresponding to ε4 shows high avidity binding to β amyloid peptide, and it is suggested that this accelerates β amyloid deposition and so the development of AD. Although numerous studies have now shown an association between the ApoE ε4 allele and both familial and sporadic late onset AD, the relationship with presenile/early onset AD (<65 years) is still controversial. Initial studies failed to find a significant association between the ApoE ε4 allele and the risk of familial early onset AD. However, most data in these early studies came from AD families with a mutation in the amyloid precursor protein (APP) gene or linked to a locus on chromosome 14. When, in later reports, patients were examined who did not have APP mutations and, based on age of onset, were less likely to be chromosome 14 linked cases, positive associations with the ApoE ε4 allele were observed. This suggests that genetic heterogeneity among early onset AD must be taken into account when interpreting ApoE associations. Charter Harlin et al. found the ε4 allele significantly raised in 34 sporadic early onset English AD cases, and Okuizumi et al. found similar findings in 44 sporadic early onset Japanese cases. The largest study of early onset AD to date, based on a population in the northern Dutch provinces and Rotterdam, gave an overall frequency for the ε4 allele in early onset AD of 35%. When patients were subdivided by family history (positive n = 107 and negative n = 68) the ε4 allele was 1.6 times higher in the family history positive group (41%) compared to the family history negative group (25%). Further analysis showed that an increased risk of early onset AD exists for ε4 homozygote carriers regardless of family history of dementia, but increased risk of early onset AD for ApoE ε4 heterozygote carriers could only be shown in subjects with a positive family history. This suggested that while a single ε4 allele increases the risk of late onset AD, alone it is insufficient to increase the risk of onset of illness before the age of 65 years. In order to address these questions further we have ApoE genotyped a cohort of severely collected Scottish cases with a definite or probable diagnosis of early onset AD and compared ApoE ε4 allele frequency in familial and sporadic cases with non-demented control groups.

Methods
PATIENT AND NORMAL DNA SAMPLES
Early onset AD (n = 85)
All met NINCDS criteria for definite (n = 19) or probable AD (n = 66). Definite cases died in either psychiatric or geriatric wards and had moderate or numerous plaques and tangles in frontal and temporal cortex and hippocampus. Cases were collected by the MRC Brain Metabolism Unit between 1979 and 1988. Probable cases were identified in hospital wards or referred by clinical colleagues throughout the central belt of Scotland. Age of onset averaged 57 years (SD 6); (28 M, 57 F). Age at onset was defined as the age at which memory loss or change in behaviour was first noticed. All cases were screened for mutations of the amy-
Apolipoprotein E4 allele status was determined on genomic DNA samples from the first three groups by polymerase chain reaction (PCR) amplification of ApoE gene sequences followed by restriction isotyping. The method used was essentially that described by Wenham et al21 with the exception that 6% metaphor agarose gels were used for product visualisation.

Results
Table 1 gives the ApoE allele frequencies for each of the four groups. Highly significant (p<0.001) differences were observed in ApoE€4 allele frequency in both early and late onset AD when compared to non-demented control groups. By contrast, no significant differences were detectable between the dementia groups themselves or between the two control groups. There was also no correlation within either group of ApoE€4 status with age of onset of AD.

Table 2 gives ApoE€4 allele numbers and percentages in early onset AD and control groups, as well as separate figures for family history positive and negative cases. Highly significant (p<0.001) differences in €4 allele numbers were found when the early onset AD group as a whole was compared to the non-demented controls or the Scottish population (χ² = 21.6 and 72.3 respectively, 2 df). These differences remained highly significant when we analysed separately the family history positive (χ² = 13.1, and 39.4, 2 df) and family history negative cases subgroups (χ² = 19.1 and 63.1, 2 df).

Table 3 gives the ODDS ratios for early onset AD associated with the ApoE€4 allele. The genotype frequencies of controls are estimated from population allele frequencies under Hardy-Weinberg assumptions. The risk of early onset AD is 4.6 times higher for carriers of at least one ApoE€4 allele compared to subjects without an ApoE€4 allele. The greatest increase is in those with a family history, but does not differ significantly from those without a family history. It is also increased more than four-fold in homozygous €4 carriers compared to heterozygous carriers.
Discussion

Our study shows an increased risk of early onset AD in ApoE ε4 allele carriers. The ε4 allele frequency was at least 2-5 times greater in the early onset AD group than in both non-demented control samples irrespective of family history, and the increase was highly statistically significant. The increased risk of early onset AD was greatest in ε4 homozygotes (16 times) but was also substantial in heterozygotes (3-7 times) compared to non-ε4 carriers. The differences between family positive and family negative cases were not statistically significant.

Our results agree, therefore, with Van Duijn et al. in showing raised ε4 allele frequency in familial early onset AD and with Chartier Harlin et al. and Okuzumi et al. in showing a raised ε4 frequency in sporadic cases. We differ from Van Duijn et al. in finding a significant (p<0.001) increase in sporadic cases of ε4 heterozygotes as well as homozygotes.

The reasons why earlier studies failed to show ApoE ε4 allele increase in early onset AD have already been discussed. They were often based on small numbers and may have lacked statistical power, but more important was selection bias. Cases examined were mostly derived from rare families with mutations of the APP gene or linked to chromosome 14. They might be expected to differ in terms of genetic risk factors from the commoner early onset cases present in the general population. Indeed when such latter cases are examined, as in the Dutch and our series, the results are remarkably similar. The only differences in the ApoE ε4 allele frequencies are in the sporadic cases where, in contrast to the Dutch series, ε4 heterozygote carriers were significantly increased. This discrepancy may be because of population differences. Also the inclusion criteria for familiality differ between the two studies. The Dutch group included as familial all cases where a first degree relative had AD, irrespective of age of onset. In our series we classified as familial cases only those with a first degree relative with early onset AD (see above). The two sets of findings are therefore not directly comparable.

The main implication of our data is that the ApoE ε4 allele is a risk factor for early onset AD. While the risk is greatest in homozygotes it is also raised in ε4 heterozygotes. It is a risk factor in familial and sporadic cases. The findings are similar to those observed in late onset AD. This means that the relative risk does not change, that is, if AD occurs in ε4 carriers it is as likely to be the commoner late onset AD as in non-ε4 carriers. However, our findings again raise the issue as to whether from a clinicopepidemiological point of view the two should not be considered as a single population. Finally, the study highlights the risk in extending to early onset AD as a whole observations made on rare subgroups of autosomal dominant families where findings may be locus specific.

We thank Alec Gordon for neuropathological assessments, Drs Moffat and Sharpe for access to patient material, and Dr. Brookes for technical advice. David St Clair is supported by the Wellcome Trust.

Apolipoprotein E epsilon 4 allele is a risk factor for familial and sporadic presenile Alzheimer's disease in both homozygote and heterozygote carriers.

D St Clair, M Rennie, E Slorach, J Norrman, C Yates and A Carothers

doi: 10.1136/jmg.32.8.642

Updated information and services can be found at:
http://jmg.bmj.com/content/32/8/642

Email alerting service

These include:
Receive free email alerts when new articles cite this article. Sign up in the box at the top right corner of the online article.

Notes

To request permissions go to:
http://group.bmj.com/group/rights-licensing/permissions

To order reprints go to:
http://journals.bmj.com/cgi/reprintform

To subscribe to BMJ go to:
http://group.bmj.com/subscribe/